Biofrontera (BFRA) Now Covered by Lake Street Capital

Lake Street Capital initiated coverage on shares of Biofrontera (NASDAQ:BFRA) in a report published on Wednesday, Marketbeat reports. The firm issued a buy rating and a $19.00 price target on the stock.

BFRA has been the topic of several other reports. ValuEngine lowered shares of Biofrontera from a hold rating to a sell rating in a research note on Monday, April 9th. Benchmark began coverage on shares of Biofrontera in a research report on Friday, March 9th. They set a buy rating and a $19.00 target price on the stock.

Biofrontera stock traded down $0.22 during mid-day trading on Wednesday, hitting $13.70. The company had a trading volume of 820 shares, compared to its average volume of 15,998. Biofrontera has a 1 year low of $11.25 and a 1 year high of $17.98. The company has a current ratio of 5.50, a quick ratio of 4.40 and a debt-to-equity ratio of 2.63.

COPYRIGHT VIOLATION NOTICE: “Biofrontera (BFRA) Now Covered by Lake Street Capital” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/04/26/biofrontera-bfra-now-covered-by-lake-street-capital.html.

Biofrontera Company Profile

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp's natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin.

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply